[PubMed] [Google Scholar] 27. 4.5%, P = 0.003) and individuals without HF (3.5% to 2.2%, P 0.001), they remained saturated in individuals with ADCHF (36.4% to 40.0%, P = 0.45) and de novo AHF (50.0% to 29.4%, P = 0.37). Although there is a rise in particular ACS therapies in Continue Reading